Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyDavid Qualls, Gilles Salles, Nicholas Lambert et al.|Blood|2023Cited by 47
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphomaAndrew Looka, Caron A. Jacobson, David Qualls et al.|Blood Advances|2024Cited by 30
Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective StudyDavid Qualls, Connie Lee Batlevi, Lori A. Leslie et al.|Blood|2022Cited by 20
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemiaJeongsook Yoon, Inhye E. Ahn, Yinglu Zhou et al.|Blood Advances|2025Cited by 12
Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US CentersEmily C. Ayers, Narendranath Epperla, Viktoriya Zelikson et al.|Blood|2023Cited by 10